Sens

Sensorion is a pioneering clinical-stage biotechnology company dedicated to developing novel therapies to restore, treat, and prevent hearing loss disorders. The company's pipeline features a diverse range of programs, including small molecule candidates and gene therapies developed in collaboration with the Institut Pasteur. Its lead small molecule candidate, SENS-401 (arazasetron), is currently being evaluated in Phase 2 trials for sudden sensorineural hearing loss and the prevention of cisplatin-induced ototoxicity. Additionally, Sensorion is advancing gene therapy programs targeting genetic forms of deafness, such as those caused by mutations in the OTOF and GJB2 genes. By leveraging its unique R&D technology platform, the company aims to address significant unmet medical needs in the global hearing health market.